AMPEL BioSolutions and ArcheMedX Form Partnership

AMPEL BioSolutions, a leading translational medicine and clinical operations company and ArcheMedX, a digital platform for effective online health care education and training programs, today announced a new collaboration to transform clinical trial recruitment and retention by enabling research sites to more effectively educate and continually engage clinical staff and patients.

The partnership will address the challenges with patient recruitment and retention for clinical trials by developing a new model for improving communication and education across study sites. By combining AMPEL’s extensive clinical expertise with the award-winning ArcheMedX e-learning and analytics platform, AMPEL and ArcheMedX will ensure that principal investigators, trial coordinators, clinical staff, and patients are well informed and continually engaged throughout the trial.

Read full press release ›

Virginia Bio Welcomes New Members to its Board of Directors

Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected five new members to their Board of Directors for a term of three years. The election took place on December 8, 2016 at the Virginia Bio Annual Membership meeting in Richmond, Virginia.

The newly elected directors are: Rony Thomas, President & CEO, LifeNet Health; Thomas Frantz, Chairman Emeritus, Williams Mullen; Julie Idelkope, Vice President, US Government Relations, Pfizer; Amrie Grammer, COO & CSO, AMPEL BioSolutions; Ross Dunlap, President & CEO, Ceres Nanosciences; and Mickey Kim, Director, Biotech Partnering & Strategy, MedImmune.

Read more: http://www.businesswire.com/news/home/20161219006218/en

Meta-Analysis of Gene Expression Data Sets to Identify Novel Molecular Pathways & Drug Targets in Systemic Lupus Erythematosus

On Tuesday, November 15, during the 2016 ACR/ARHP Annual Meeting, Dr Peter Lipsky will give a talk entitled “Meta-Analysis of Gene Expression Data Sets to Identify Novel Molecular Pathways & Drug Targets in Systemic Lupus Erythematosus” during the “Mining Big Data for Drug Repurposing” session. The presentation will begin at 11:00 AM in room 146A.

For more information visit: http://acrannualmeeting.org/wp-content/uploads/2016/06/2016-Program-Preview.pdf

Data mining could lead to therapy advances

In the past 50 years, only one new therapy has been approved for the treatment of lupus.

Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts during the Clinical Science symposium Mining Big Data for Drug Repurposing.

The symposium will take place from 11:00 am – 12:00 pm on Tuesday in room 146A and will demonstrate the potential role of genetics and data mining strategies in identifying new or repurposed therapeutic targets for systemic autoimmune rheumatic diseases.

Read more… http://www.acrdailynewslive.org/data-mining-could-lead-to-therapy-advances/